In the 4T1-induced breast cancer model, the combination therapy with GSK484 and dual checkpoint blockade of PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) showed synergistic enhancement of the effects of both monotherapies [180]. Here, CTLA4 is linked to breast cancer.